
Latest – new solutions, webinars and updates
-
NeuMoDx COVID-19 solutions added to the QIAGEN portfolioQIAGEN fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems
-
QIAGEN confirms effectiveness of its SARS-CoV-2 PCR testsQIAstat-Dx, NeuMoDx tests, and QIAseq SARS-CoV-2 Primer Panels continue to detect viral mutations extremely effectively.
-
QIAGEN launches SARS-CoV-2 test for T cell responseQIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T cell response
icon-support
How can we support your lab?
Reach a specialist about SARS-CoV-2 resources.
In the United States:
QIAreach SARS-CoV-2 Antigen testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, to perform high complexity tests.
The QIAreach SARS-CoV-2 Antigen Test has been validated but FDA's independent review of this validation is pending.
Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.
QIAreach SARS-CoV-2 Antigen testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, to perform high complexity tests.
The QIAreach SARS-CoV-2 Antigen Test has been validated but FDA's independent review of this validation is pending.
Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.